Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Blood (2021) 138 (Supplement 1): 369.

https://doi.org/10.1182/blood-2021-150371

Published: 2021

Journal Articles

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Marissa Locastro, BS, Kah Poh Loh, MBBCHBAO, Andrea M. Baran, MS, Jane L. Liesveld, MD, Michael W. Becker, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Omar S. Aljitawi, MD, Megan Baumgart, MD, Eric Snyder, Benzi Kluger, MD, Jason H. Mendler, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139475

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Jodi J Lipof, MD, Dharmini Manogna, MD, Andrea M. Baran, MS, Bassil Said, MD, Michael W. Becker, MD, Jason H. Mendler, MD PhD, Omar S. Aljitawi, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Richard Burack, MD PhD, Margaret Blaney, Taylor Douglas, Jane L. Liesveld, MD, Kah Poh Loh, MBBCHBAO

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136739

Published: 2020

Journal Articles

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Luke Eastburg, MD, David A. Russler-Germain, MDPhDBS, Ramzi Abboud, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Michael W. Becker, MD, Neha Kumar, MD, Omar S. Aljitawi, MD, Jeffrey R. Andolina, MD MS, Thomas J Fountaine, MD, Jane L. Liesveld, MD, Eric Huselton, MD

Blood (2019) 134 (Supplement_1): 4496.

https://doi.org/10.1182/blood-2019-129872

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Eric Huselton, MD, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Meagan Jacoby, MD PhD, Iskra Pusic, MD, Rizwan Romee, MD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD

Blood (2017) 130 (Supplement 1): 5067.

https://doi.org/10.1182/blood.V130.Suppl_1.5067.5067

Published: 2017

Journal Articles

Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS

Eric Huselton, MD, Rizwan Romee, MD, Michael Slade, BA, Cory Jenson

Blood (2016) 128 (22): 2278.

https://doi.org/10.1182/blood.V128.22.2278.2278

Published: 2016

NARROW

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only